Intuniv® Is Preferred (DAW 6) Over Its Generic

In order for the State to enhance the benefit of the PDL, in some instances the multisource brand name drug is Preferred over its generic equivalents, because the branded drug is less costly than its generic counterpart. This happens most often in cases of newly released generics. When manufacturer rebates are taken into consideration, the brand name drug has a lower net cost to the State.

Effective Wednesday, December 17, 2014, MMPP will cover brand Intuniv® over its generic counterpart (guanfacine extended-release tablets). Claims for Intuniv® must be submitted with DAW 6 and will be priced appropriately. Claims for Intuniv® with any other DAW code will reject. A DHMH Medwatch form will not be required.

- If any problems are encountered during the on-line claim adjudication of Preferred Brands, contact Xerox 24-hour Help Desk at 800-932-3918 for additional system overrides related to the use of the correct DAW code (for example, if there is other primary insurance). All Advisories are available online on DHMH’s web link at:
  http://mmcp.dhmh.maryland.gov/pap/SitePages/Provider%20Advisories.aspx